EIT Pharma Raises $35M Series A for Hepatitis D and Infectious Disease Pipeline

EIT Pharma, a Kirkland, Washington-based clinical-stage biotechnology company, has secured $35 million in Series A funding. The round was led by Propel Bio Partners, with participation from Good Ventures Foundation and Arrowtown. The investment will support the development of the company's lead program, lonafarnib, an investigational oral candidate for chronic hepatitis D, which is currently under FDA review.

Addressing Unmet Medical Needs

EIT Pharma focuses on developing therapies for infectious diseases with significant unmet medical needs. Its pipeline includes treatments for chronic hepatitis D and acute respiratory infections. Lonafarnib, if approved, would be the only oral late-stage therapy option for chronic hepatitis D, offering advantages such as oral dosing and room-temperature storage.

Series A Funding Details

The funding round was completed on August 31, 2026. The lead investor, Propel Bio Partners, was joined by Good Ventures Foundation and Arrowtown. The total amount raised is $35 million USD.

About EIT Pharma

EIT Pharma is dedicated to advancing innovative treatments for infectious diseases. With this new capital, the company is poised to advance its pipeline and potentially bring a much-needed oral therapy to patients with chronic hepatitis D.